GenEdit

About:

GenEdit develops next generation therapeutics for genetic diseases through safe and efficient CRISPR/Cas9 delivery.

Website: http://www.genedit.com

Top Investors: Sequoia Capital, Eli Lilly, National Science Foundation, Huons, Qiming Venture Partners

Description:

GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. The company's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases.